spacer
home > epc > spring 2002 > drug information association's 14th annual euromeeting - basel, switzerland, 5th-8th march 2002
PUBLICATIONS
European Pharmaceutical Contractor

Drug Information Association's 14th Annual EuroMeeting - Basel, Switzerland, 5th-8th March 2002

The 14th annual DIA EuroMeeting is based on the premise that in the 21st Century only a relatively small proportion of all diseases can be adequately treated, nevermind cured. At a fundamental level there is a lack of understanding of the mechanism of disease - particularly the genetic basis of disease and its implications for rational drug treatment.

Of equal concern is that only a small proportion of all patients have access to safe medicinal products at affordable prices. The availability of safe and effective medicines is a real issue in third world countries where for many patients the cost of diagnosis and treatment are beyond their means. This leads to counterfeit and often dangerous substitutes being sold in those countries. Where treatments are available there is often a lack of clear information on the products and their rational use.

Regulatory authorities, government health departments and medical insurance companies add their own particular and specific hurdles to the early availability of effective treatments.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Richard Barrett of Pfizer Global Research and Development, UK

Richard Barrett of Pfizer Global Research and Development, UK is the Co-Chairperson of the Euro2002 Programme Committee, along with Manuel Zahn, of AstraZeneca, Sweden.
spacer
Richard Barrett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement